Channing Capital Management LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 106,740 shares of the biopharmaceutical company’s stock after buying an additional 5,216 shares during the period. Channing Capital Management LLC’s holdings in Gilead Sciences were worth $7,555,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the business. American Research & Management Co. boosted its stake in shares of Gilead Sciences by 24.0% during the 2nd quarter. American Research & Management Co. now owns 14,725 shares of the biopharmaceutical company’s stock valued at $1,042,000 after buying an additional 2,850 shares during the period. Great West Life Assurance Co. Can boosted its stake in shares of Gilead Sciences by 5.8% during the 2nd quarter. Great West Life Assurance Co. Can now owns 1,768,836 shares of the biopharmaceutical company’s stock valued at $125,005,000 after buying an additional 96,802 shares during the period. Alpha Cubed Investments LLC boosted its stake in shares of Gilead Sciences by 2.3% during the 2nd quarter. Alpha Cubed Investments LLC now owns 32,742 shares of the biopharmaceutical company’s stock valued at $2,317,000 after buying an additional 748 shares during the period. DT Investment Partners LLC boosted its stake in shares of Gilead Sciences by 17.7% during the 2nd quarter. DT Investment Partners LLC now owns 19,039 shares of the biopharmaceutical company’s stock valued at $1,348,000 after buying an additional 2,869 shares during the period. Finally, Texas Capital Bancshares Inc. TX acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at $245,000. 73.97% of the stock is owned by institutional investors.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Over the last three months, insiders sold 466,819 shares of company stock worth $36,740,240. Insiders own 1.30% of the company’s stock.
GILD has been the subject of a number of research reports. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price objective for the company in a research note on Wednesday, September 6th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, July 27th. ValuEngine lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 price objective (up previously from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Eleven analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $84.29.
ILLEGAL ACTIVITY NOTICE: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://stocknewstimes.com/2017/09/21/channing-capital-management-llc-raises-holdings-in-gilead-sciences-inc-gild.html.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 82.64 on Thursday. The firm’s 50-day moving average is $77.54 and its 200 day moving average is $70.38. The company has a market capitalization of $107.92 billion, a PE ratio of 8.98 and a beta of 1.19. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the company earned $3.08 EPS. The business’s revenue was down 8.2% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences, Inc. will post $8.78 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.